Cargando…
Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
BACKGROUND: Active demethylation of 5-methyl-2′-deoxycytidine (5-mdC) in DNA occurs by oxidation to 5-(hydroxymethyl)-2′-deoxycytidine (5-hmdC) and further oxidation to 5-formyl-2′-deoxycytidine (5-fdC) and 5-carboxy-2′-deoxycytidine (5-cadC), and is carried out by enzymes of the ten-eleven transloc...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977551/ https://www.ncbi.nlm.nih.gov/pubmed/29875879 http://dx.doi.org/10.1186/s13148-018-0505-0 |
_version_ | 1783327397993512960 |
---|---|
author | Dziaman, Tomasz Gackowski, Daniel Guz, Jolanta Linowiecka, Kinga Bodnar, Magdalena Starczak, Marta Zarakowska, Ewelina Modrzejewska, Martyna Szpila, Anna Szpotan, Justyna Gawronski, Maciej Labejszo, Anna Liebert, Ariel Banaszkiewicz, Zbigniew Klopocka, Maria Foksinski, Marek Marszalek, Andrzej Olinski, Ryszard |
author_facet | Dziaman, Tomasz Gackowski, Daniel Guz, Jolanta Linowiecka, Kinga Bodnar, Magdalena Starczak, Marta Zarakowska, Ewelina Modrzejewska, Martyna Szpila, Anna Szpotan, Justyna Gawronski, Maciej Labejszo, Anna Liebert, Ariel Banaszkiewicz, Zbigniew Klopocka, Maria Foksinski, Marek Marszalek, Andrzej Olinski, Ryszard |
author_sort | Dziaman, Tomasz |
collection | PubMed |
description | BACKGROUND: Active demethylation of 5-methyl-2′-deoxycytidine (5-mdC) in DNA occurs by oxidation to 5-(hydroxymethyl)-2′-deoxycytidine (5-hmdC) and further oxidation to 5-formyl-2′-deoxycytidine (5-fdC) and 5-carboxy-2′-deoxycytidine (5-cadC), and is carried out by enzymes of the ten-eleven translocation family (TETs 1, 2, 3). Decreased level of epigenetic DNA modifications in cancer tissue may be a consequence of reduced activity/expression of TET proteins. To determine the role of epigenetic DNA modifications in colon cancer development, we analyzed their levels in normal colon and various colonic pathologies. Moreover, we determined the expressions of TETs at mRNA and protein level. The study included material from patients with inflammatory bowel disease (IBD), benign polyps (AD), and colorectal cancer (CRC). The levels of epigenetic DNA modifications and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) in examined tissues were determined by means of isotope-dilution automated online two-dimensional ultraperformance liquid chromatography with tandem mass spectrometry (2D-UPLC-MS/MS). The expressions of TET mRNA were measured with RT-qPCR, and the expressions of TET proteins were determined immunohistochemically. RESULTS: IBD was characterized by the highest level of 8-oxodG among all analyzed tissues, as well as by a decrease in 5-hmdC and 5-mdC levels (at a midrange between normal colon and CRC). AD had the lowest levels of 5-hmdC and 5-mdC of all examined tissues and showed an increase in 8-oxodG and 5-(hydroxymethyl)-2′-deoxyuridine (5-hmdU) levels. CRC was characterized by lower levels of 5-hmdC and 5-mdC, the lowest level of 5-fdC among all analyzed tissues, and relatively high content of 5-cadC. The expression of TET1 mRNA in CRC and AD was significantly weaker than in IBD and normal colon. Furthermore, CRC and AD showed significantly lower levels of TET2 and AID mRNA than normal colonic tissue. CONCLUSIONS: Our findings suggest that a complex relationship between aberrant pattern of DNA epigenetic modification and cancer development does not depend solely on the transcriptional status of TET proteins, but also on the characteristics of premalignant/malignant cells. This study showed for the first time that the examined colonic pathologies had their unique epigenetic marks, distinguishing them from each other, as well as from normal colonic tissue. A decrease in 5-fdC level may be a characteristic feature of largely undifferentiated cancer cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13148-018-0505-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5977551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59775512018-06-06 Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease Dziaman, Tomasz Gackowski, Daniel Guz, Jolanta Linowiecka, Kinga Bodnar, Magdalena Starczak, Marta Zarakowska, Ewelina Modrzejewska, Martyna Szpila, Anna Szpotan, Justyna Gawronski, Maciej Labejszo, Anna Liebert, Ariel Banaszkiewicz, Zbigniew Klopocka, Maria Foksinski, Marek Marszalek, Andrzej Olinski, Ryszard Clin Epigenetics Research BACKGROUND: Active demethylation of 5-methyl-2′-deoxycytidine (5-mdC) in DNA occurs by oxidation to 5-(hydroxymethyl)-2′-deoxycytidine (5-hmdC) and further oxidation to 5-formyl-2′-deoxycytidine (5-fdC) and 5-carboxy-2′-deoxycytidine (5-cadC), and is carried out by enzymes of the ten-eleven translocation family (TETs 1, 2, 3). Decreased level of epigenetic DNA modifications in cancer tissue may be a consequence of reduced activity/expression of TET proteins. To determine the role of epigenetic DNA modifications in colon cancer development, we analyzed their levels in normal colon and various colonic pathologies. Moreover, we determined the expressions of TETs at mRNA and protein level. The study included material from patients with inflammatory bowel disease (IBD), benign polyps (AD), and colorectal cancer (CRC). The levels of epigenetic DNA modifications and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) in examined tissues were determined by means of isotope-dilution automated online two-dimensional ultraperformance liquid chromatography with tandem mass spectrometry (2D-UPLC-MS/MS). The expressions of TET mRNA were measured with RT-qPCR, and the expressions of TET proteins were determined immunohistochemically. RESULTS: IBD was characterized by the highest level of 8-oxodG among all analyzed tissues, as well as by a decrease in 5-hmdC and 5-mdC levels (at a midrange between normal colon and CRC). AD had the lowest levels of 5-hmdC and 5-mdC of all examined tissues and showed an increase in 8-oxodG and 5-(hydroxymethyl)-2′-deoxyuridine (5-hmdU) levels. CRC was characterized by lower levels of 5-hmdC and 5-mdC, the lowest level of 5-fdC among all analyzed tissues, and relatively high content of 5-cadC. The expression of TET1 mRNA in CRC and AD was significantly weaker than in IBD and normal colon. Furthermore, CRC and AD showed significantly lower levels of TET2 and AID mRNA than normal colonic tissue. CONCLUSIONS: Our findings suggest that a complex relationship between aberrant pattern of DNA epigenetic modification and cancer development does not depend solely on the transcriptional status of TET proteins, but also on the characteristics of premalignant/malignant cells. This study showed for the first time that the examined colonic pathologies had their unique epigenetic marks, distinguishing them from each other, as well as from normal colonic tissue. A decrease in 5-fdC level may be a characteristic feature of largely undifferentiated cancer cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13148-018-0505-0) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-30 /pmc/articles/PMC5977551/ /pubmed/29875879 http://dx.doi.org/10.1186/s13148-018-0505-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Dziaman, Tomasz Gackowski, Daniel Guz, Jolanta Linowiecka, Kinga Bodnar, Magdalena Starczak, Marta Zarakowska, Ewelina Modrzejewska, Martyna Szpila, Anna Szpotan, Justyna Gawronski, Maciej Labejszo, Anna Liebert, Ariel Banaszkiewicz, Zbigniew Klopocka, Maria Foksinski, Marek Marszalek, Andrzej Olinski, Ryszard Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease |
title | Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease |
title_full | Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease |
title_fullStr | Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease |
title_full_unstemmed | Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease |
title_short | Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease |
title_sort | characteristic profiles of dna epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977551/ https://www.ncbi.nlm.nih.gov/pubmed/29875879 http://dx.doi.org/10.1186/s13148-018-0505-0 |
work_keys_str_mv | AT dziamantomasz characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT gackowskidaniel characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT guzjolanta characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT linowieckakinga characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT bodnarmagdalena characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT starczakmarta characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT zarakowskaewelina characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT modrzejewskamartyna characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT szpilaanna characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT szpotanjustyna characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT gawronskimaciej characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT labejszoanna characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT liebertariel characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT banaszkiewiczzbigniew characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT klopockamaria characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT foksinskimarek characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT marszalekandrzej characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT olinskiryszard characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease |